Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings

STOK·Reported May 7, 2026·After market close

Stoke Therapeutics, Inc. reported Q1 2026 revenue of $6.2M (-96.1% YoY), missed analyst consensus of $6.5M by $254.3K. Diluted EPS came in at $-0.79, beat the $-0.80 consensus by $0.01.

Revenue
$6.2Mmissed by $254.3K
Consensus: $6.5M
Diluted EPS
$-0.79beat by $0.01
Consensus: $-0.80
SEC

SEC Filings

Earnings release8-K · 0001193125-26-212020
Quarterly report10-Q · 0001193125-26-211874

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Stoke Therapeutics, Inc.'s Q1 2026 earnings report.

Stoke Therapeutics, Inc. (STOK) reported Q1 2026 earnings on May 7, 2026 after market close.

Stoke Therapeutics, Inc. reported revenue of $6.2M and diluted EPS of $-0.79 for Q1 2026.

Revenue missed the consensus estimate of $6.5M by $254.3K. EPS beat the consensus estimate of $-0.80 by $0.01.

Compared to the same quarter a year prior, revenue declined 96.1% from $158.6M a year earlier.

You can read the 8-K earnings release (0001193125-26-212020) and the 10-Q periodic report (0001193125-26-211874) directly on SEC EDGAR. The filing index links above go to sec.gov.